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Obesity is an important component of the pathophysiology of chronic diseases. Identifying epigenetic modifications associated
with elevated adiposity, includingDNAmethylation variation,may point to genomicpathways that are dysregulated innumerous
conditions. The Illumina 450K Bead Chip array was used to assay DNAmethylation in leukocyte DNA obtained from 2097 African
American adults in the Atherosclerosis Risk in Communities (ARIC) study. Mixed-effects regressionmodels were used to test the
association of methylation beta value with concurrent body mass index (BMI) and waist circumference (WC), and BMI change,
adjusting for batch effects and potential confounders. Replication using whole-blood DNA from 2377 White adults in the
FraminghamHeart Study and CD4+ T cell DNA from 991Whites in the Genetics of Lipid Lowering Drugs and Diet Network Study
was followed by testing using adipose tissue DNA from 648 women in the Multiple Tissue Human Expression Resource cohort.
Seventy-six BMI-related probes, 164 WC-related probes and 8 BMI change-related probes passed the threshold for significance in
ARIC (P < 1 × 10−7; Bonferroni), including probes in the recently reportedHIF3A, CPT1A andABCG1 regions. Replication using blood
DNAwas achieved for 37 BMI probes and 1 additional WC probe. Sixteen of these also replicated in adipose tissue, including
15 novel methylation findings near genes involved in lipid metabolism, immune response/cytokine signaling and other diverse
pathways, including LGALS3BP, KDM2B, PBX1 and BBS2, among others. Adiposity traits are associated with DNA methylation at
numerous CpG sites that replicate across studies despite variation in tissue type, ethnicity and analytic approaches.
Introduction
Epigenetics is the study of mitotically heritable modifications in
chromatin structure not involving the underlying DNA sequence,
and their impact on the transcriptional control of genes and cel-
lular function. Of the different forms of epigenetic modification,
DNA methylation is the most extensively studied and involves
the addition and removal of methyl (-CH3) groups at CpG dinu-
cleotides to influence regional DNA transcription (1). Although
genome-wide demethylation and re-methylation occur during
embryogenesis and established patterns must be set to initiate
differentiation and maintain cell type-specific gene expression
(2), DNA methylation and other features of the epigenome are
also modifiable throughout the life course by environmental
and behavioral exposures such as the nutrient content of the
maternal diet (3), cigarette smoking (4) and environmental
pollutants (5). Because of their role in gene expression, alterations
in epigenetic patterns are amechanism bywhich these and other
environmental factors may increase risk of disease (6,7).
As individuals accrue excess adipose tissue, they experience
chronic low-grade inflammation, associatedwith immunological
activation and oxidative stress (8,9), as well as insulin resistance,
hypertension and dyslipidemia (10). These features explain, in
part, why obesity is among the strongest modifiable risk factors
for diabetes, atherosclerosis and some cancers (11–19). In an epi-
genetic framework, obesity can be seen as an environmental
factor that exposes the genome in many tissues to a suite of
systemic factors [e.g. elevated circulating C-reactive protein,
interleukin (IL) 6], potentially altering DNA methylation or his-
tone protein acetylation patterns. Identifying epigenetic modifi-
cations associated with obesity may therefore point to genomic
pathways that are dysregulated in numerous conditions.
As of 2015, only a small number of studies had been published
showing obesity-related variation in DNA methylation, with
most studies generally using either targeted repeat sequence
(global methylation) or candidate gene-centric approaches.
With some exceptions (20,21), such studies have not yielded re-
sults that have been replicated in independent cohorts (reviewed
by Drong et al.) (7). Recent technological advances have provided
platforms for systematically interrogating DNAmethylation vari-
ation across the genome (22), paving theway for epigenome-wide
association studies (EWASs), analogous to genome-wide associ-
ation studies, to identify regions of the genome-harboring DNA
methylation variation associated with disease phenotypes (6).
EWASs of obesity traits have shown that methylation variants
are influenced by nearby genetic variants (i.e. are haplotype
specific) as in the case of the well-documented obesity gene
FTO (23–26). To date, only one obesity EWAS has yielded a novel
replicated locus (CpG sites in HIF3A) (27), and only one obesity
EWAS has been conducted in African Americans (25), despite
the fact that African-ancestry groups tend to carry higher chronic
disease risk factor loads, including greater obesity, compared
with European-ancestry populations (28–30).
The goal of the present investigation is to advance our under-
standing of the methylation signatures associated with obesity
traits using leukocyte DNA samples from over 2000 African
American adults, many of whom were overweight or obese at
the time of DNA collection, with replication in three independent
cohorts. Our findings replicate those from recent EWAS of body
mass index (BMI), lipid and diabetes-related traits and identify
a number of novel associations with BMI, waist circumference
(WC) and BMI change. The results are a step toward understand-
ing the pathophysiology of obesity and identifying new molecu-
lar targets to avert its negative health consequences.
Results
Description of discovery sample
The ARIC Study is a prospective cohort study of cardiovascular
disease risk in White and Black adults from four US communi-
ties (31). Subjects were seen at baseline (Visit 1) in 1987–1989,
with four follow-up visits (Visits 2–5) thereafter. The study sam-
ple for the present investigation (N = 2097; 64% female) includes
only those with methylation data (all of whom are African
American). Average age was 56 years at the time of Visit 2
when DNA methylation data and adiposity measures were
both available. Subjects had mean BMI, WC and BMI change of
30.1 kg/m2, 101.3 cm and 7.0 kg/m2 (6.0), respectively. Most of
the subjects were overweight (37%) or obese (44%) and 67%
exceeded National Heart, Lung, and Blood Institute (NHLBI)-
recommended WC limits (>88 cm for women and >102 cm for
men). Prevalent diabetes was present in 26% of the participants.
Imputed white blood cell (WBC) count differentials were
obtained for all subjects, and the mean proportions of each
cell type aswell as other study covariates are provided inTable 1.
A flowchart (Fig. 1) outlines the results of the subsequent ana-
lyses, detailed later.
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Gene pathway analysis
To test the global hypothesis that there are significant associa-
tions of adiposity traits with methylation variation, we con-
ducted a genome-wide gene ontology (GO) pathway analysis for
BMI andWC including all CpGs, using the same statisticalmodels
as in the subsequent EWAS. The approach accounted for the de-
gree of clustering of probes included in the HM450 in particular
genes and gene regions. Results yielded significant [false discov-
ery rate (FDR)-adjusted q-value < 0.05] enrichment of over 100
biological process pathways for BMI and 90 biological process
pathways for WC (Supplementary Material, Tables S1 and S2),
involving 11–204 genes per pathway. These pathways represent
a diverse range of processes, particularly related to neuronal
function (e.g. neuronmigration andneuroblast proliferation), im-
mune response/cytokine signaling (e.g. humoral immune re-
sponse and positive regulation of IL-6 production) and energy
and fatty acid metabolism [e.g. tricarboxylic acid (Krebs’) cycle
and arachidonic acid secretion].
Association study
Manhattan plots showing the −log10 P-values for individual auto-
somal CpG probe associations for BMI and WC are provided in
Table 1. Characteristics of the study sample: N = 2097 African American adults in the ARIC study
Mean (SD) Range N
Age (years) 56.2 (5.7) 47–70 2097
BMI (kg/m2) 30.1 (6.1) 14.7–62.4 2096
WC (cm) 101.3 (15.1) 61–163 2097
BMI change (kg/m2) 7.0 (6.0) −25.9–36.4 2039
Physical activity (scale of 1–5)a 2.1 (0.6) 1–4.25 2097
WBC count (1000/mm3) 5.6 (1.9) 2.0–28.8 2097
N (proportion)
Sex
Male 763 (0.36) 2097
Female 1334 (0.64)
Field center
Forsyth County, NC 157 (0.07) 2097
Jackson, MS 1940 (0.93)
BMI statusb
Underweight (BMI < 18.5 kg/m2) 19 (0.01) 2095
Normal weight (BMI 18.5–24.99 kg/m2) 369 (0.18)
Overweight (BMI 25.0–29.99 kg/m2) 789 (0.37)
Obese (≥30.0 kg/m2) 918 (0.44)
WC statusb
Normal 698 (0.33) 2097
Elevated 1399 (0.67)
Cigarette smoking
Current smoker 512 (0.24) 2097
Current nonsmoker 1585 (0.76)
Alcohol use
Current drinker 717 (0.34) 2097
Current nondrinker 1380 (0.66)
Education
<High school 843 (0.40) 2097
High school graduate 581 (0.28)
>High school 673 (0.32)
Household income
<$16 000 1087 (0.52) 2097
$16 000–$24 999 379 (0.18)
$25 000–$34 999 278 (0.13)
$35 000–$49 999 202 (0.10)







No 1539 (0.74) 2087
Yes 548 (0.26)
aSelf-reported leisure time physical activity using the Baecke Questionnaire at Visit 1.
bBMI status: underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5–24.99 kg/m2), overweight (BMI 25.0–29.99 kg/m2) and obese (≥30.0 kg/m2). WC status: low risk
(WC ≤88 cm for women and ≤102 cm for men) and high risk (WC >88 cm for women and >102 cm for men).
cDifferential WBC proportions were imputed using the method of Houseman et al. (32) using measured differentials from a subset of 179 ARIC subjects as the reference.
dPrevalent diabetes at the time of the DNA collection was defined as a self-reported physician diagnosis of or treatment for diabetes.
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Figure 2. A total of 76 probes passed the threshold for genome-
wide significance for BMI, and 164 probes passed this threshold
for WC. For BMI change, eight probes passed this threshold, all
of which were also among the statistically significant BMI
and/or WC probes (P < 1 × 10−7) (Supplementary Material,
Table S3), including cg15871086 (Chr. 18 intergenic, P = 8.77E −
10), cg09554443 (near CD247, P = 2.68E − -09), cg00574958 [near
carnitine palmitoyltransferase-1A (CPT1A), P = 4.30E − 08] and
cg16672562 [near hypoxia-inducible factor 3 (HIF3A), P = 8.60E −
08]. CPT1A methylation probe associations have been recently
reported to be associated with atherogenic lipoprotein subfrac-
tions in the Genetics of Lipid Lowering Drugs and Diet Network
(GOLDN) cohort (33). Methylation at cg16672562 near HIF3Awas
recently reported to be associated with BMI in ∼2500 European
adults in the Cardiogenetics Consortium, MARseille THrombosis
Association and Cooperative Health Research in the Region of
Figure 1. Flowchart of experiments and summary of results.
Figure 2. Manhattan plot of CpG methylation association −log10 P-values in 2107 African American adults in the ARIC study. (A) BMI and (B) WC.
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Augsburg cohorts (27). BMI change associations arenot discussed
in further detail due to their complete overlap with BMI and WC
results.
Regression coefficients, standard errors, P-values and CpG
marker information for the significant associations for BMI and
WC in the ARIC discovery sample are provided in Supplementary
Material, Tables S4 and S5, respectively. For BMI, the top CpG
(cg06500161, P = 1.52E − 13) explained ∼2.6% of variation in BMI
and is located in a CpG island shore in the gene body of ABCG1
[ATP-binding cassette, subfamily G (WHITE), member 1]. This
gene is expressed in blood plasma and platelets and is involved
inmacrophage cholesterol and phospholipids transport, and cel-
lular regulation of lipid homeostasis (34).ABCG1 promoter hyper-
methylation is strongly associated with coronary heart disease
(CHD) (35), and this particular CpG was also associated with
insulin-related traits in the GOLDN cohort (33). A second CpG
site near ABCG1 also was among the top results (cg27243685, P =
3.61E − 08). The two CpGs are ∼14 kb distant from one another;
their mean methylation beta values were significantly different
from one another (mean beta value for cg006500161 = 0.62;
mean beta value for cg27243685 = 0.85; unpaired t-test P-value <
0.0001) and weremoderately inter-correlated (r = 0.32; P < 0.0001).
Other loci exhibiting two ormore significant CpG associations in-
cluded the smoking-relatedmethylation locus AHRR (cg23576855
and cg05575921),HIF3A (cg27146050, cg22891070 and cg16672562)
with the same three CpG sites previously reported by Dick et al.
(27) to be associatedwith BMI, the innate immune response regu-
lator NFKBIL1 (cg21053741 and cg21587837), the histone H3 de-
methylase KDM2B (cg15695155, cg26995224 and cg13708645),
the natural killer immune response gene LGALS3BP (cg04927537
and cg25178683) and NWD1 of unknown function (cg15845821
and cg19344626). Conditional regression models (which required
switching BMI to the dependent variable) were run for loci with
>1 CpG association and showed no evidence for multiple inde-
pendent signals within these loci. After ABCG1 and AHRR, the
third-ranked CpG association was near the CD247 gene, involved
in T-cell receptor signaling, immune response and IL-12-induced
interferon gamma (IFNγ) production. As a note, it is likely that the
observed CpG associations near AHRR were the result of residual
confounding; our EWAS was conducted using smoking coded as
current/noncurrent, andwhenwe further adjusted the results for
former smoking and total pack years of smoking, the associa-
tions with BMIwere greatly attenuated and no longer statistically
significant (data not shown).
There was considerable overlap between results for BMI and
WC; 56 of the BMI associations (74%) were also significant for
WC and the top CpG was the same for both traits (cg06500161
near ABCG1, P for WC = 4.41E − 19). This CHD-associated marker
explained ∼3.6% of variation in WC. The second-ranked probe
in the WC analysis was cg00574958 (P = 5.79E − 17) near CPT1A,
also mentioned earlier. Additional high-ranking probes in
our WC EWAS included a site near LY6G6E (cg13123009, P = 1.8 ×
10–13), which belongs to a cluster of leukocyte antigen-6 (LY6)
genes located in the major histocompatibility complex (MHC)
class III region on chromosome 6, and C7orf50, a longevity locus
(36). It is generally noted that probes passing the threshold for
significance for BMI and WC in ARIC explained 0.2–3.6% trait
variance, included CpG sites across the spectrum of average
methylation values (minimum 0.04 to maximum 0.95 mean
methylation) and had intra-class correlation (ICC) coefficient va-
lues for replicates of >0.35 (Supplementary Material, Tables S4
and S5). Most CpG markers had ICC > 0.60, suggesting higher
probe reliability/quality as measured by ICC increases the prob-
ability of detecting association.
Replication of association results
We took forward the 76 BMI-associated probes for replication in
the Framingham Heart Study (FHS) (methylation data for which
subjects were generated in one of two laboratories and consid-
ered separately here) and GOLDN. Details on the replication
cohorts are found in the Supplementary Text. Direction and
P-value for each BMI probe are provided by cohort, and meta-
analysis P-values for the replication (FHS I + FHS II + GOLDN) are
provided in Table 2. The direction of association was consistent
across both replication cohorts for 47/76 BMI probes [62%, z stat-
istic for equal proportions for null hypothesis that each of two co-
horts was concordant with ARIC (null = 12.5%, or 0.5 × 0.5 × 0.5);
z = 5.66, P = 0.0001]. Of these 47, meta-analysis P-value was <6.6 ×
10−4 for 37 CpG probes. Top probes were those mentioned earlier
near CPT1A (global meta-analysis P-value = 3.4 × 10–47), near
ABCG1 (global P-value = 1.0 × 10–46), in an intergenic region on
Chr 17 (cg03078551, P = 6 × 10–28) and near SREBF1 (cg11024682,
P = 2.8 × 10–24) (sterol regulatory element-binding transcription
factor 1), which is intimately involved in cholesterol biosyn-
thesis, producing a product that binds the sterol regulatory elem-
ent-1 (SRE-1), flanking the low density lipoprotein (LDL) receptor
gene. Interestingly, the HIF3A probes initially reported by Dick
et al. (27) to be associated with BMI, and that we confirmed in
African Americans earlier, did not replicate in leukocyte DNA
from Whites in FHS and GOLDN.
Of the 164WC-associated probes taken forward for replication
in GOLDN, 140 (85%) had consistent direction of association [z-
statistic for equal proportions for null hypothesis of concordance
with ARIC (null = 50%); z = 3.79, P = 0.0001]. Of these 140, 8 also
passed the 3 × 10−4 significance threshold for replication, 1 of
which was unique to WC: DHCR24 (Table 3). DHCR24 (3-beta-
hydroxysterol delta-24-reductase) catalyzes reduction of sterol
intermediates during the final step of cholesterol biosynthesis
and is of current interest as a biomarker of nonalcoholic hepatic
steatosis. DHCR24 gene expression changes track strongly with
weight loss after bariatric surgery (37).
Influence of cis-acting SNPs
As a global test ofwhether these associations are potentially con-
founded by any cis-acting single nucleotide polymorphisms
(SNPs), we identified SNPs in a 500-kb window (250 kb up and
down stream) of each of the 37 replicated BMI probes (see
below) and determined their associations with BMI in an existing
large GWAS meta-analysis conducted in ∼40 000 African Ameri-
can adults (38). Supplementary Material, Table S6 lists the SNP
name having the lowest P-value for association with BMI in
each 500-kb region (referred to as the ‘reference SNP’). All such
SNPs were associated with BMI at P = 1 × 10−5 or higher. This ana-
lysis shows that replicated methylation associations reported
here are unlikely to be confounded by the effect of common cis-
acting SNPs on BMI in African Americans.
Secondary Analysis 1: impact of prevalent diabetes on
replicated associations
Because increased adiposity is a risk factor for type 2 diabetes,
and because diabetes and its treatmentmay impactmethylation,
we tested the degree to which association results were altered by
covariate adjustment for concurrent diabetes status, a possible
mediator of the adiposity–DNA methylation relationship. Sup-
plementary Material, Table S7 presents a side-by-side compari-
son of beta values and P-values when diabetes is, and is not,
included as a covariate for the 37 replicated BMI probes and the
4468 | Human Molecular Genetics, 2015, Vol. 24, No. 15
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cg00574958 11 CPT1A −0.0029 3.23E− 12 −12.881 5.77E− 38 −−−− 3.44E− 47 55.9 6.801 0.0785
cg06500161 21 ABCG1 0.0081 1.52E− 13 12.456 1.29E− 35 ++++ 1.01E− 46 77.8 13.543 0.0036
cg03078551 17 NA −0.0026 7.49E− 09 −9.399 5.52E− 21 −−−− 6.03E− 28 1.4 3.042 0.3851
cg11024682 17 SREBF1 0.0068 9.58E− 09 8.424 3.63E− 17 ++++ 2.76E− 24 55.6 6.755 0.0801
cg13123009 6 LY6G6E;
LY6G6D
0.0069 1.80E− 11 6.894 5.41E− 12 ++++ 1.01E− 21 0 1.657 0.6466
cg04927537 17 LGALS3BP 0.0108 5.91E− 10 7.17 7.48E− 13 ++++ 2.93E− 21 0 2.45 0.4845
cg27243685 21 ABCG1 0.0057 3.61E− 08 7.661 1.85E− 14 ++++ 4.23E− 21 61.3 7.747 0.0515
cg26403843 5 RNF145 0.0099 1.06E− 08 6.934 4.09E− 12 ++++ 2.51E− 19 0 0.567 0.9040
cg09349128 22 NA −0.0059 1.44E− 08 −6.92 4.51E− 12 −−−− 3.76E− 19 0 0.507 0.9173
cg07814318 15 KLF13 0.0081 2.33E− 10 5.896 3.73E− 09 ++++ 1.19E− 17 73.8 11.445 0.0095
cg07573872 19 SBNO2 −0.0069 2.80E− 08 −6.377 1.80E− 10 −−−− 3.00E− 17 0 0.683 0.8771
cg13708645 12 KDM2B 0.0096 4.68E− 10 5.74 9.48E− 09 ++++ 6.03E− 17 60.7 7.631 0.0543
cg25178683 17 LGALS3BP 0.0087 1.67E− 08 6.138 8.36E− 10 ++++ 9.25E− 17 0 0.869 0.8328
cg12992827 3 NA −0.0075 5.31E− 09 −5.939 2.87E− 09 −−−− 1.25E− 16 47.3 5.693 0.1275
cg09664445 17 KIAA0664 0.0055 8.89E− 09 5.93 3.03E− 09 ++++ 2.08E− 16 65.4 8.672 0.0340
cg06876354 2 RALB 0.0057 1.02E− 09 5.62 1.91E− 08 ++++ 2.53E− 16 39 4.916 0.1780
cg23998749 1 NA 0.0052 5.66E− 08 5.92 3.22E− 09 ++++ 1.14E− 15 40.4 5.035 0.1692
cg06192883 15 MYO5C 0.0065 5.29E− 08 5.791 7.01E− 09 ++++ 2.45E− 15 0 0.979 0.8062
cg26033520 10 NA 0.0070 1.44E− 08 5.578 2.43E− 08 ++++ 3.01E− 15 0 1.065 0.7856
cg07136133 11 PRR5L −0.0048 6.70E− 09 −5.36 8.34E− 08 −−−− 6.24E− 15 0 1.871 0.5996
cg08972190 7 MAD1L1 0.0054 6.43E− 10 5.054 4.33E− 07 ++++ 6.42E− 15 27.7 4.149 0.2458
cg06946797 16 NA −0.0070 8.35E− 09 −5.131 2.88E− 07 −−−− 3.04E− 14 17.2 3.622 0.3052
cg18568872 15 ZNF710 0.0062 3.74E− 10 4.709 2.49E− 06 ++++ 3.54E− 14 66.8 9.04 0.0288
cg15871086 18 NA 0.0062 8.31E− 11 4.354 1.34E− 05 ++++ 1.00E− 13 67.5 9.226 0.0264
cg08857797 17 VPS25 0.0063 3.40E− 09 4.74 2.14E− 06 ++++ 1.55E− 13 39.9 4.99 0.1725
cg20954977 2 B3GNT7 0.0101 1.68E− 08 4.898 9.66E− 07 ++++ 2.13E− 13 21.3 3.811 0.2826
cg04816311 7 C7orf50 0.0090 2.56E− 12 3.823 1.32E− 04 ++++ 2.18E− 13 77.1 13.094 0.0044
cg14017402 2 NA 0.0080 1.47E− 10 4.226 2.38E− 05 ++++ 3.17E− 13 75.9 12.462 0.0060
cg17560136 8 EPB49 0.0063 3.03E− 08 4.824 1.41E− 06 ++++ 5.27E− 13 25.3 4.018 0.2595
cg11592786 15 NA −0.0031 3.60E− 08 −4.584 4.56E− 06 −−−− 2.36E− 12 14.8 3.52 0.3181
cg01844514 7 ZNF862 0.0046 3.17E− 08 4.27 1.96E− 05 ++++ 1.21E− 11 4.5 3.143 0.3701
cg18307303 5 IL12B 0.0044 4.67E− 08 4.217 2.48E− 05 ++++ 2.16E− 11 46.4 5.592 0.1332
cg04869770 1 PBX1 0.0057 5.65E− 09 3.805 1.42E− 04 ++++ 4.23E− 11 57.6 7.074 0.0696
cg00863378 16 BBS2 0.0055 1.91E− 08 3.967 7.27E− 05 ++++ 4.24E− 11 49.5 5.939 0.1146
cg26354221 22 ADORA2A 0.0032 1.39E− 08 3.725 1.95E− 04 ++++ 1.20E− 10 52.7 6.343 0.0961
cg15695155 12 KDM2B 0.0079 4.03E− 08 3.802 1.43E− 04 ++++ 1.71E− 10 49 5.883 0.1175
cg27614723 15 SLCO3A1 0.0071 5.62E− 08 3.62 2.94E− 04 ++++ 5.44E− 10 39.4 4.947 0.1757
aSuccessful replication was defined as consistent direction of association across all four studies (ARIC, FHS I, FHS II and GOLDN) and P < 0.05/76 (<6.6 × 10−4) in the
replication meta-analysis. Meta-analysis used Stouffer’s Z for trend test, which is based on meta-analysis of P-values with adjustment for cohort sample size and
direction.















cg13708645 12 KDM2B 0.0098 7.22E− 11 0.0074 1.28E− 05 ++ 4.52E − 15
cg11024682 17 SREBF1 0.0080 3.52E− 12 0.0039 1.33E− 05 ++ 2.37E − 16
cg03078551 17 intergenic −0.0025 8.16E− 09 −0.0021 1.74E− 05 −− 6.61E − 13
cg06192883 15 MYO5C 0.0083 1.50E− 12 0.0031 2.56E− 05 ++ 2.15E − 16
cg26403843 5 RNF145 0.0101 2.38E− 09 0.0044 7.53E− 05 ++ 7.92E − 13
cg13123009 6 LY6G6E 0.0074 1.81E− 13 0.0032 8.25E− 05 ++ 1.07E − 16
cg06500161 21 ABCG1 0.0096 4.41E− 19 0.0043 9.39E− 05 ++ 1.09E − 21
cg17901584 1 DHCR24 −0.0080 8.34E− 08 −0.0049 2.39E− 04 −− 8.15E − 11
aSuccessful replication was defined as consistent direction of association in GOLDN and ARIC and P-value of <0.05/164 (<3 × 10−4) in the replication cohort. Meta-analysis
used Stouffer’s Z for trend test, which is based on meta-analysis of P-values with adjustment for cohort sample size and direction.
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1 additional replicated WC probe (above). Generally, regression
coefficients were reduced by 5–25% with adjustment, but 19/37
of BMI-associated probes and 0/1 of theWC probes remained sig-
nificant at P < 1 × 10−7. These results show that about half of the
BMI–DNA methylation associations we report are independent
of concurrent diabetes, and the others remain strongly asso-
ciated even with adjustment for this condition.
Secondary Analysis 2: replication in adipose tissue
samples
The 37 BMI probes and 1 WC methylation probe that independ-
ently replicated in FHS andGOLDNwere subjected to cross-tissue
association study using adipose tissue DNA (Table 4). Replication
was based on P-value only, because it was assumed that the dir-
ection of effect of the same exposure on DNA methylation may
differ in different tissue types. Twenty-eight of the 38 probes
passed quality control (QC) inMultiple Tissue Human Expression
Resource (MuTHER), and of these, 18/28 (64%) were associated
with BMI in adipose tissue at P < 1.9 × 10−3, including markers
near the previously identified CPT1A and ABCG1 loci, but also a
large number of novel adiposity-related loci, including LYS6GE,
KDM2B, RALB, PRRL5, LGALS3BP, C7orf50, PBX1, EPB49 and BBS2.
BBS2 [Bardet–Biedl syndrome (BBS) 2] is one of the BBS genes in-
volved in cilia formation, cell movement and cell signaling. Auto-
somal recessive variants in BBS2 are among those responsible for
BBS, which is characterized by severe obesity and numerous de-
velopmental aberrations. Overall, the results show wide cross-
tissue agreement in BMI– and WC–methylation associations.
Discussion
Our study presents the first EWAS of adiposity traits in African
American adults, demonstrating numerousmethylation variants
associated with BMI and WC, including 37 CpG site associations
for BMI and 1 additional association forWC that replicated in two
European-ancestry cohorts. The ARIC results included sites in
three loci (near HIF3A, CPT1A and ABCG1) that have been previ-
ously reported to be associated with BMI, insulin-related traits
and lipid subfractions (27,33,41,42), as well as a number of
novel loci. This demonstrates to our knowledge the first cross-
ethnic replication of methylation signals for BMI from the
HM450K array. Further, the results show that despite differences
in blood cell type (GOLDN used CD4+ T cells, ARIC and FHS used
whole blood), normalization approach [GOLDN used COMBAT
followed by polynomial regression normalization (43), FHS used
wateRmelon and Beta MIxture Quantile dilation (BMIQ) (44) and
ARIC used BMIQ] and some variation in the average age of the co-
horts and specific covariate adjustments, there was general con-
sistency of results across these large, independent EWAS studies
of adiposity traits. This is important because while epigenetic
modification in cancer etiology has been established for more
than a decade (45,46), identification of epigenetic patterns in-
volved in cardiometabolic disease and its precursors (e.g. obesity)
has yielded relatively few replicated loci (reviewed by Drong et al.)
(7). There has been concern that the large potential for confound-
ing in epigenetic studies would make successful replication diffi-
cult. What is likely more important to successful replication of
adiposity associations is sample size; effect sizes observed in
this study were relatively small, with the marginal variance in
methylation beta value at individual CpG sites explained by a 1
SD difference in BMI or WC ranging from 0.25 to 2.4%.
ARIC participants gained an average of 7 kg/m2 over the
30-year period from age 25 to Visit 2. BMI change was associated
with eight different CpG sites, including the highly cited methy-
lation variant near CPT1A, showing that numerous novel methy-
lation loci identified in our study donot only index currentweight
status or its correlates but may also be involved in changes in
body weight over time. Generally, we observed extensive overlap
in the methylation associations for the three adiposity traits in-
vestigated; of the 38 replicated CpG associations for BMI/WC, 4
were shared by all 3 traits, and 27 were shared by BMI and WC
(see Fig. 3 for a diagram of overlap across the 3 traits).
Significant obesity or weight gain/weight loss associations
have been reported for CpG methylation sites near SLC6A4 (47),
MEST (48), NPY (49), POMC (49), PGC-1α and PDK4 (50). Existing
studies tend to be small (generally <200 subjects per group),
which likely explains the lack of replication. Exceptions include
replicated methylation associations near POMC (20) and RXRA
(21). None of these CpG sites from previously reported regional
or candidate gene association studies was significantly asso-
ciated with BMI, WC or BMI change in the present analysis. We
also did not replicate the methylation variants recently found
to change in response toweight loss (51) or increased physical ac-
tivity (52). A recent genome-wide BMI methylation study con-
ducted in 48 obese and 48 lean African American children did
not report associations at the CpG site level but indicated that dif-
ferentially methylated regions with greater inter-individual vari-
ance in methylation are enriched in obesity, as in cancer (25).
To date, the only prior EWAS to identify and robustly replicate
methylation variants associatedwith BMI is that of Dick et al. (27).
That study reported methylation at three CpG sites in intron 1 of
HIF3A to be positively associated with BMI in both blood and adi-
pose tissue DNA in European adults (27). Here, we replicate the
positive association for three of these probes in blood DNA
from African Americans (cg22891070, cg16672562 and cg27146050)
with BMI and between cg16672562 methylation and BMI change.
As described previously by Dick et al. (27), these probes are
within likely regulatory elements (open chromatin regions) and
are potentially functional; moreover, methylation level was
inversely associated with HIF3A gene expression at one of the
five expression probes examined. HIF3A is a component of
the hypoxia-inducible transcription factor (HIF) involved in the
physiological response to hypoxia but is also implicated in adipo-
cyte differentiation (53) and is expressed in response to glucose
and insulin changes (54). However, we found that these HIF3A
methylation probes were not associated with BMI in either the
FHS or the GOLDN study. The reason for this inconsistent replica-
tion is unclear butmay relate to the greater obesity comorbidities
(perhaps including inflammatory status) in ARIC (e.g. diabetes)
and the original study population (over 50% of whom had a his-
tory of myocardial infarction), when compared with the replica-
tion cohorts in this analysis.
Our unbiased pathway analysis of the EWAS data shows that
over 100 biological pathways are significantly enriched for
methylation association with BMI and WC, including those
involved in lipid and energy metabolism, immune function, adi-
pocyte, neuronal and chondrocyte differentiation and develop-
ment, and many others. These results suggest that further
work in larger cohort studies may identify many additional
methylation variants in associationwith adiposity and its related
traits. Many of the specific loci identified in this study are known
to be involved in lipid and lipoprotein metabolism, including the
known differentially methylated locus CPT1A (involved in mito-
chondrial uptake of long-chain fatty acids and triglyceride me-
tabolism) and ABCG1 (involved in macrophage cholesterol and
phospholipids transport, and lipid homeostasis), as well as the
novel BMI-related methylation site near SREBF1, which gene
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Table 4. Replicated BMI CpG sites significantly associated in both leukocyte and adipose tissue DNA from 648 females in the MuTHER, in order of MuTHER P-valuea








cg17560136 EPB49 0.00233 Yes 4.64E− 33 Erythrocyte membrane protein band 4.9: gene product essential for the maintenance of erythrocyte
shape and membrane stability
cg04869770 PBX1 0.00222 Yes 8.53E− 25 Pre-B-cell leukemia transcription factor involved in pancreatic development and function, candidate
gene SNPs associated with obesity, variants may influence porcine adipose tissue fatty acid
composition
cg25178683 LGALS3BP 0.00305 Yes 1.68E− 18 Lectin, galactoside-binding, soluble, 3 binding protein: a macrophage inflammatory marker, arterial
expression upregulated in response to obesity in animal models
cg01844514 ZNF862 0.00111 Yes 4.72E− 16 Zinc finger protein 862: protein coding gene of unknown function, may be involved in transcriptional
regulation
cg07136133 PRR5L −0.00392 Yes 7.85E− 15 Proline rich 5-like: regulates cytoskeleton organization and interacts with mTOR, a central controller of
cell growth, to increase apoptosis
cg06876354 RALB −0.00129 No 9.40E− 14 RAS-related small GTP-ase B: involved in a variety of cellular processes including gene expression and
has role in colorectal cancer oncogenesis
cg26033520 Intergenic Chr. 10 0.00244 Yes 5.29E− 12 Unknown
cg08857797 VPS25 −0.00172 No 5.85E− 12 Vacuolar protein-sorting-associated protein 25: part of endosomal sorting complexes required for
transport protein, II (ESCRT-II) complex involved in endosomal transport and possibly gene
transcription
cg06946797 Intergenic Chr. 16 −0.00145 Yes 2.09E− 09 Unknown
cg04816311 C7orf50 −0.00152 No 2.27E− 09 Chromosome 7 open reading frame 50; unknown function, GWAS variants in this locus are associated
with lipid levels and longevity
cg00574958 CPT1A −0.00032 Yes 3.40E− 08 Carnitine palmitoyltransferase-1A: involved in mitochondrial uptake of long-chain fatty acids and
triglyceride metabolism, previously associated with insulin-related DNA methylation
cg13123009 LY6G6E 0.00072 Yes 1.18E− 07 Lymphocyte antigen-6 complex, locus G6E (pseudogene): one of LY6 genes located in the MHC class III
region, immune function, acute lymphoblastic leukemia, hematopoiesis, cell adhesion
cg13708645 KDM2B 0.00184 Yes 1.74E− 07 Lysine K-specific demethylase 2B: a H3K36 histone demethylase, involved in cellular senescence, tumor
cell differentiation, part of a complex that represses preadipocyte differentiation
cg26403843 RNF145 −0.00203 Yes 5.59E− 07 Ring finger protein 145: unknown function
cg00863378 BBS2 0.00113 Yes 7.21E− 07 BBS-2: member of the BBS gene family. BBS is an autosomal recessive disorder characterized by severe
obesity, developmental abnormalities and mental retardation
cg09664445 KIAA0664 0.00077 Yes 9.84E− 06 Aka CLUH, clustered mitochondria homolog: regulates mitochondrial biogenesis
cg18568872 ZNF710 0.00094 Yes 1.85E− 05 Zinc finger 710: protein-coding gene, function unknown, may be involved in transcriptional regulation
cg15871086 Intergenic Chr. 10 0.00094 Yes 1.46E− 03 Unknown
WC
cg17901584 DHCR24 0.00162 No 9.07E− 13 3-Beta-hydroxysterol delta-24-reductase: catalyzes reduction of sterol intermediates during final step of
cholesterol biosynthesis, biomarker of nonalcoholic hepatic steatosis, expression changes associated
with weight loss after bariatric surgery
aThe MuTHER includes genome-wide DNA methylation data (Illumina HumanMethylation450 array) from abdominal subcutaneous adipose tissue collected from 648 female twins (39,40).
bFixed-effects regression coefficient from linear mixed models (LMM), with probe DNA methylation beta value as the dependent variable and BMI as the primary independent variable, covariate adjusted for age, bisulfite conversion
concentration, bisulfite conversion efficiency and experimental batch (Beadchip) (fixed effects), and family relationship (twin-pairing) and zygosity (random effects).
cReplication was based on P-value only because increased or decreasedmethylationmay differ by tissue type. Threshold for replication was set at P < 1.8 × 10−3 (0.05/28 tests). There were 37 BMI-associated CpGs and 1WC-associated












encodes a transcription factor that binds to the LDL receptor and
other genes involved in sterol biosynthesis. Promoter variants in
SREBF1 influence hepatic cholesterol and steatosis in rats (55) and
with diabetes traits in humans (56,57). Immune function and in-
flammatory pathways are also strongly represented in our novel
loci, including IL-12B, NFKBIL1, LY6G6E, SBNO2 (part of the IL-10
anti-inflammatory signaling pathway) and LGALS3BP (lectin ga-
lactoside-binding soluble 3 binding protein). LGALS3BP expres-
sion was recently found to be one of a small group of genes
whose expression is strongly modulated throughout the arterial
network in response to obesity (58). This study together with our
findings suggests how obesity-related methylation variants
could be useful as targets for cardiovascular disease treatment
and prevention. To move this work forward, the functional sig-
nificance of themethylation variants discovered heremust be es-
tablished and a determination made that they mediate the
relationships of obesity to diabetes and CHD, rather than that
they are downstream effects of the obesity-related disease.
In that regard, wewere interested inwhether the associations
identified with adiposity traits were likely mediated by or other-
wise dependent on the presence of diabetes, which condition
was common in our study sample (26%), is strongly related to
obesity and is associated with methylation variation (e.g. 26,59).
Although in half of the sites, P-values were no longer genome-
wide significant after covariate adjustment for prevalent dia-
betes, all of the associations remained strong (P < 1 × 10−5), with
an average change in regression coefficient of only 11.2%. Thus,
while some adiposity-related methylation signals may be due
to underlying insulin resistance or diabetes, these results suggest
thatmanymay be properly characterized as fundamentally obes-
ity related. Longitudinal analysis of weight gain in individuals
without diabetes will confirm these findings.
Blood is an accessible and plentiful tissue for genomic ana-
lysis in large studies, but there are two major concerns regarding
its use in epigenetic studies of obesity and cardiometabolic con-
ditions: biological relevance and confounding by cell type
differential. In terms of relevance, obesity may be characterized
as a defect in appetite/satiety regulation resulting in elevated cir-
culating free fatty acids, leading to adipocyte differentiation to
sequester the excess lipids. The most biologically relevant tissue
types for the analysis of obesity-related gene expression (and,
ergo, methylation) might therefore include the hypothalamus,
liver and adipose tissue. It is encouraging that many of the sig-
nals we detected in WBCs also replicated in adipose tissue. Not
all did so, perhaps due to gender differences: MuTHER is 100%
female while the studies using blood included both males and
females. It has been shown that different tissues including
brain, lung, thyroid, saliva and whole blood exhibit highly con-
cordant age associations (60) and that smoking is associated
with consistent AHRR methylation profiles in both lymphoblasts
and pulmonarymacrophages (61). Such studies suggest thatDNA
methylation in blood can serve as a biomarker of methylation in
other tissues, as found here.
Another concern regarding the use of blood in epigenetic epi-
demiologic investigations is that it contains multiple cell types,
each having a characteristic methylation profile, such that DNA
methylation associations with disease could be confounded by
the relative proportions of different cell types in the DNA sample
(62). Indeed, mean methylation percent differed significantly be-
tween blood cell types for over 70 000 of the CpG sites on the
HM450 (63). This was less of a concern here in that there was
no association between WBC differential and obesity at Visit 1
in ARIC (when measured differentials were available for the en-
tire cohort). In addition, covariate adjustment for imputed WBC
differentials did not substantially alter our EWAS results, and
we replicated our results in different tissue/cell types, both of
which procedures reduce the probability that the results are
solely due to confounding by cell type distribution.
Despite its disadvantages, an advantage of leukocytes for
epigenetic studies of obesity is that adiposity and immunological
activation are strongly causally related. When individuals gain
excessive body fat, numerous changes in the immune system
Figure 3. Overlap in EWAS results for BMI, WC and BMI change in ARIC African American adults.
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occur, including increases inWBCs and alterations in the produc-
tion of different leukocytes, including increases in neutrophils,
mast cells, CD8+ T cells and some classes of monocytes
and decreases in T regulatory cells and eosinophils. These
changes in immune cell distribution reduce the production of
anti-inflammatory IL-10 and increase the production of pro-
inflammatory IL-6, IFNγ and tumor necrosis factor alpha
(TNFα), among other cytokine changes (64). After substantial
weight loss, leukocyte counts and differentials normalize, as
seen following bariatric surgery (65), which suggests that weight
gain and loss drive changes in low-grade inflammation and leuko-
cyte cell types rather than the reverse. Thus, methylation signals
found in blood may be potentially useful biomarkers of obesity-
related inflammatory damage, as indicated by the many
inflammation-related loci identified in the current analysis.
The present study has a number of limitations, the most im-
portant of which is the cross-sectional design, which does not
allow for clear temporal relationships between predictor (e.g.
BMI) and outcome (CpG-specific methylation) to be assessed
and leaves open the potential for reverse causality. Studies in-
cluding non-obese individuals with DNA methylation assess-
ment at that time point with follow-up for incident obesity and
DNA methylation changes at a later point would provide clarifi-
cation on methylation variants that drive the development of
obesity as opposed to those that are affected by obesity. Second,
gene expression data were not available in ARIC to confirm the
functional relevance of the DNA methylation variation we have
identified. However, the CPT1A, HIF3A and ABCG1 probes we
report have been found to influence gene expression in prior
studies (27,41).
The study also had numerous strengths, including a relatively
large discovery sample, whichmay have been responsible for the
larger number of significant findings than has been reported pre-
viously for BMI, a focus on African Americans, which is import-
ant due to their higher burden of obesity and related conditions
but poorer coverage by current EWAS studies, and control for nu-
merous potential confounders and batch effects, including a test
of potentially cis-acting SNPs in each of the methylation regions
for association with BMI, and covariate adjustment for imputed
cell type differentials. Other strengths include examination
of multiple adiposity traits, a relatively large replication sample
(N = 3368) with additional replication in adipose tissue as well
(N = 648), quantification of probe-specific measurement error/
reliability and consideration of the role of diabetes in the
associations.
In conclusion, this study confirmed three previously identified
methylation loci suggested to be associated with obesity and
related traits (CPT1A, ABCG1 and HIF3A) and identified numerous
additional novel loci harboring individual DNA methylation vari-
ation inbothblood andadipose tissue that are associatedwith adi-
posity traits in African American adults. Results were successfully
replicated across studies despite variation in tissue type, ethnicity
and analytic approaches. Experimental and longitudinal study
designs, and larger multi-cohort analyses, are needed to assess
causalityand tomove thegrowingfield of epigenetic epidemiology
toward richer insight into the biology of obesity, as well as new
therapies to reduce or reverse its downstream effects on health.
Methods and Procedures
Population
The ARIC Study is a prospective cohort study of cardiovascular
disease risk in four US communities (31). Between 1987 and
1989, 7082men and 8710 women aged 45–64 years were recruited
from Forsyth County, North Carolina; Jackson, Mississippi (Afri-
can Americans only); suburban Minneapolis, Minnesota; and
Washington County, Maryland. The ARIC Study protocol was ap-
proved by the institutional review board of each participating
university. After written informed consent was obtained, includ-
ing that for genetic studies, participants underwent a baseline
clinical examination (Visit 1) and four subsequent follow-up clin-
ical exams (Visits 2–5). At this time, DNA methylation data are
available for African American members of the cohort only,
and the present study comprises a cross-sectional analysis of
these data. Specifically, a single DNA sample was chosen for
methylation analysis for each subject, and BMI,WCand covariate
data detailed below were from the same study visit. For these
analyses, all data come from Visit 2, except as noted below for
physical activity. In addition, self-reported weight at age 25 (col-
lected only at Visit 1) was used to calculate weight change from
age 25 to Visit 2 as a measure of adulthood BMI change.
Measurements and questionnaires
Anthropometrics were taken with the subject wearing a scrub
suit and no shoes. BMI was calculated from measured weight
and height (weight in kilograms/height in meters squared). WC
was measured at the level of the umbilicus using a flexible
tape. WBC count was assessed by automated particle counters
within 24 h after venipuncture in the local hospital hematology
laboratory. The reliability coefficient for theWBC countmeasure-
ment was >0.96 (66). MeasuredWBC differentials were only avail-
able for a subset at Visit 2 (N = 187), but these were used in the
imputation of differential WBCs for the remaining subjects (see
below for description). Questionnaires assessed education
(coded as less than high school degree, high school degree or
equivalent and greater than high school degree), current house-
hold income, current cigarette smoking (coded as current, former
and never smoked), current alcohol consumption status (coded
as current/former/never) andmedical history (67). Level of leisure
time physical activity was assessed at Visit 1 using the Baecke
questionnaire (68). Leisure time activity scores range in whole
and half increments from 1 to 5, with values <2 indicative of
physical inactivity (69). Prevalent diabetes was defined as a fast-
ing glucose level of ≥126 mg/dl (70), nonfasting glucose of
≥200 mg/dl or a self-reported physician diagnosis of or treatment
for diabetes.
Bisulfite conversion of DNA
Genomic DNA was extracted from peripheral blood leukocyte
samples using the Gentra Puregene Blood Kit (Qiagen; Valencia,
CA, USA) according to the manufacturer’s instructions (www.
qiagen.com). Bisulfite conversion of 1 ug genomic DNAwas per-
formed using the EZ-96 DNAMethylation Kit (DeepWell Format)
(Zymo Research; Irvine, CA, USA) according to the manufac-
turer’s instructions (www.zymoresearch.com). Bisulfite conver-
sion efficiency was determined by PCR amplification of the
converted DNA before proceeding with methylation analyses
on the Illumina platform using Zymo Research’s Universal
Methylated Human DNA Standard and Control Primers.
Illumina infinium methylation assay
The Illumina Infinium HumanMethylation450K Beadchip array
(HM450K) (described by Sandoval et al.) (71) was used to measure
DNA methylation (Illumina, Inc.; San Diego, CA, USA). The
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platform detects methylation status of 473 788 CpG sites by se-
quencing-based genotyping of bisulfite-treated DNA. Bisulfite
treatment converts only unmethylated cyosines to uracils, allow-
ing for highlymultiplexed genotyping with single site resolution.
The array covers 96% of CpG Islands (as well as CpG shores) and
98.9% of RefSeq genes with a global average of 17.2 probes per
gene region and has been shown to have high accuracy and reli-
ability (72,73).
Bisulfite-converted DNA was used for hybridization on the
HM450K BeadChip, following the Illumina Infinium HD Methyla-
tion protocol (www.illumina.com). This consisted of a whole
genome amplification step followed by enzymatic end-point
fragmentation, precipitation and re-suspension. The re-sus-
pended samples were hybridized to the complete set of bead-
bound probes, followed by ligation and single-base extension
during which a fluorescently labeled nucleotide is incorporated
and scanned. The degree of methylation is determined for each
CpG cytosine by measuring the amount of incorporated label
for each probe. The intensities of the images were extracted
using Illumina GenomeStudio 2011.1, Methylation module 1.9.0
software. The methylation score for each CpG was represented
as a beta (β) value according to the fluorescent intensity ratio.
Beta values may take any value between 0 (nonmethylated) and
1 (completely methylated). Background subtraction was con-
ducted with the GenomeStudio software using built-in negative
control bead types on the array.
Normalization
The HM450K uses two different probe types (I and II). Due to dif-
ferences in design, probes using the Illumina Type II assay are
less sensitive for the detection of extreme methylation values
(i.e. 0 and 1) than the Type I assay and have greater average vari-
ance between technical replicates (74). BMIQ (75) was used in this
analysis to adjust the beta values of type 2 design probes into a
statistical distribution characteristic of type 1 probes. BMIQ
has been shown to more effectively reduce probe set bias and
technical error across replicates compared with some other
peak-based and quantitative normalization procedures (76). An
emerging conclusion is that in general, the improvements offered
by different normalization approaches are modest, with very
high concordance in association results across differentmethods
(77). Further, in this study,we conducted all analyses at the single
probe level, and therefore, any differences in probe type should
not strongly influence the results.
Quality control
Positive and negative controls and sample replicates were in-
cluded on each 96-well plate assayed. After exclusion of controls,
replicates and samples with integrity issues or failed bisulfite
conversion, a total of 2841 study participants had HM450K data
available for further QC analyses.We removed poor-quality sam-
pleswith pass rate of <99%, that is, if the sample had at least 1%of
CpG siteswith detection P-value > 0.01 ormissing (N = 37), indica-
tive of lower DNA quality or incomplete bisulfite conversion, and
sampleswith a possible gendermismatch based on evaluation of
selected CpG sites on the Y chromosome (N = 2), leaving a total of
2802 samples available for analysis. At the target level, weflagged
poor-quality CpG sites with average detection P-value of >0.01
and calculated the percentage of samples having detection P-
value of >0.01 for each autosomal and X chromosome CpG site.
There were 9399 autosomal and X chromosomal markers where
>1% of samples showed detection P-value of >0.01, and these
sites were excluded. In addition, we filtered 370 CpG sites on
the Y chromosomewith average detection P-value of >0.01, leav-
ing a total of 473 788 CpG sites for analysis.
Technical error analysis
To obtain a measure of probe-specific technical error and the
reliability of the methylation measures, technical replicates
were included for 130 samples (total n = 265 with 5 samples repli-
cated 3 times), from which ICC coefficients for methylation beta
values were calculated for all probes (78). Further information on
the method is provided in the Supplementary Text.
Statistical analysis
Of the 2802 samples available after methylation QC, 705 did not
have complete covariate data needed for confounder adjustment,
leaving a final sample size of N = 2097 (2096 with BMI and BMI
change data and 2097 with WC data). Mean, standard deviation
and range, or frequencies, are provided to describe continuously
distributed and categorical variables, respectively. Methylation
data were tested and reported in terms of beta values, ranging
from 0 to 100%. While beta values have non-constant variance
across different CpG sites, they have the clear advantage of repre-
senting the percentage methylation for each site and are there-
fore more easily interpretable than M values, which are the log2
ratio of the intensities of the methylated versus unmethylated
probes. Further, it has been shown that in large sample sizes as
in ARIC, test statistics are similar for M and beta values (79).
Pathway analysis
Complete methylation and phenotype data were first subjected
to pathway analysis for an a priori test of genomic pathway en-
richment for the association of BMI orWCwithDNAmethylation.
The Illumina 450 K probe annotation file contains (non-unique)
mappings of 75% of the CpG sites to 21 160 genes, based upon
the closest gene to each methylation probe. Reflecting our pur-
pose in detecting entire genomic pathways that are enriched
for individually small methylation signals, and long-standing
practice in pathway analysis of GWAS SNP data, gene-level
methylation signal measurements were first summarized by
averaging across all probes annotated to each gene (80). Biocon-
ductor was used to assign genes to the GO domains (molecular
function, cellular component and biological process), for a total
of 6700 GO pathways tested. Pathway enrichment methods that
are not resampling based have been shown to be highly anti-con-
servative (81). We performed pathway testing while rigorously
controlling false positives by using the safeExpress R package
(82), controlling for the same covariates as specified below. We
used the safeExpress test statistic D, which is a competitive statis-
tic contrasting genes in each pathway versus the complement
(82). For each GO domain, the output provided pathway global
statistics and P-values, where correction for multiple compari-
sons was performed using Benjamini–Hochberg FDR q-values
(83). The FDR is relatively robust to positive correlation structures
(84), which are often strong in pathway analysis and thus enables
effective multiple test correction in a manner that is not overly
conservative. FDR q < 0.05was considered statistically significant.
Association study
Batch effect adjustment is critical in the analysis of HM450K data,
and ComBat is an Empirical Bayes method frequently used to
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adjust gene expression and other microarray data for potential
batch effects (85). In preliminary analyses, we found very high
concordance in EWAS results for BMI with and without ComBat
adjustment of the beta values in our linear mixed-effect regres-
sion models (LMMs) to address batch effects, where batch effect
was accounted for by adding plate number (1–34) and chip row
number (1–6) as fixed effects and chip number (1–244) as a ran-
dom effect. Therefore, we used the simpler LMMwithout ComBat
adjustment for subsequent analyses. We specified the regression
modelswith probemethylation beta value as the dependent vari-
able, andwith adiposity traits and all covariates as the independ-
ent variables. We chose this approach because the technical (e.g.
batch) effects we wished to adjust for pertain to the beta values,
not to BMI, and also because in our study of older African Ameri-
can adults, weight gain and obesity are long-standing character-
istics of the participants over their lives,whichwepositmayhave
influences on DNA methylation (rather than being influenced
by DNA methylation).
Cross-sectional LMM were tested using the R package lme4
with methylation beta values as the dependent variable, and
with chip specified as a randomeffect and the following variables
specified as fixed effects: standardized adiposity variable (BMI,
WC and BMI change with mean = 0 and SD = 1), sex, age, study
center, total WBC, education, household income, current cigar-
ette smoking, current alcohol consumption, leisure time physical
activity and 10 PCs from the Illumina Infinium HumanExome
Beadchip genotype array (86), to account for potential confound-
ing by genetic ancestry. The regression models were further
adjusted for leukocyte cell type proportions (neutrophils, lym-
phocytes,monocytes and eosinophils) as additional fixed effects.
Cell-type proportions were imputed using the algorithm devel-
oped by Houseman (40), which utilizes the known cell type speci-
ficity of methylation at selected CpG probes on the HM450 to
impute cell type proportions, and based on the measured differ-
ential cell counts available for a subset of ARIC participants at
Visit 2. The choice of covariates was based upon known or sus-
pected confounding, as described in the directed acyclic graph
presented in Supplementary Material, Figure 1S. The Wald test
was applied to test the hypothesis that BMI, WC or BMI change
(depending on the model tested) was associated with CpG
methylation.
Following standard practice in association analysis (87), mul-
tiple test correctionswere used to control the family-wise error at
0.05. Applying a standard Bonferroni correction for the 473 788
CpG sites gives P < 1 × 10−7 as the significance threshold. Signifi-
cant EWAS results for each trait were then filtered to remove
known cross-reactive probes and polymorphic CpGs (88).
A secondary analysis addressed whether the adiposity–
methylation associations were independent of diabetes by in-
cluding prevalent diabetes status (yes/no) in the above regression
model. To account for multiple comparisons, a Bonferroni-
corrected P-value of < 1 × 10−7 was used as the threshold for
determining whether CpG methylation remained significantly
associated with adiposity independent of diabetes status.
Replication analysis
CpG sites with association P-values of <1 × 10−7 for BMI and WC
were carried forward for replication in 991 members of the
GOLDN cohort (mean age = 49 years, mean BMI = 28 kg/m2,
female = 52%, prevalent diabetes = 7.6%, ancestry = 100% Euro-
pean-American, tissue = CD4 +T cells) and 2377 members of the
FHS Offspring (mean age = 67 years, mean BMI = 28 kg/m2, %
female = 56%, prevalent diabetes = 13.4%, ancestry = 100%
European-American, tissue =whole blood). Both studies utilized
blood DNA and the same HM450 platform for methylation ana-
lysis as inARIC.Methylation assayswere performed at two differ-
ent laboratories in the FHS and thus are considered as two
independent cohorts for replication. Further details of the two
replication cohorts are provided in the Supplementary Text.
Given the different analytic strategies and blood cell types used
among the discovery and replication studies (detailed in the Sup-
plementary Text), the meta-analysis was conducted on P-values
(not beta values) using a sample size-weighted method (Stouf-
fer’s Z trend) that also incorporated the direction of the beta coef-
ficients (89) and was implemented in R. For BMI, replication in
blood DNAwas defined as consistent direction of the beta coeffi-
cient in all four cohorts, and a Bonferroni-corrected meta-
analysis P-value for the replication cohorts (FHS I, FHS II and
GOLDN) of <0.05/76 or P < 6.6 × 10−4. For WC, replication was
only available in the GOLDN cohort, and probe associations
were considered to have positively replicated based on consist-
ency of the direction of effect and a Bonferroni-corrected
P-value based on the number of probes tested (164 probes,
0.05/164 = P < 3 × 10−4).
Test for confounding by cis-acting genetic variants
Methylation SNPs, defined as SNPs within probe sequences, were
filtered as stated earlier. As a more general means of excluding
the possibility that our results are confounded by cis-acting
SNPs, we examined the 500-kb regions surrounding each of our
top BMI-associatedmethylation probes to search for SNPassocia-
tions with BMI using data from a recent large meta-analysis and
report the lowest P-values for each region. Thismeta-analysis ex-
amined the association of >3.2 million SNPs (imputed using the
1000 Genomes Project) with BMI in 39 144 men and women of
African ancestry (38).
Cross-tissue replication
Concerns regarding tissue specificity of CpG site methylation
and the relevance of peripheral blood leukocytes for obesity
were addressed in a secondary analysis by testing the association
of the replicated CpG probes identified for BMI (N = 37) and WC
(N = 1) using adipose tissue DNA. The MuTHER contains
genome-wide DNA methylation data using the HM450 array in
subcutaneous abdominal adipose tissue collected from 648 Euro-
pean-ancestry female twins and singletons (97 MZ pairs, 162 DZ
pairs and 130 singletons) (39,40). The subjects had a mean age of
∼60 years and a mean BMI of 26.6 kg/m2. Further details on the
MuTHER cohort materials and methods are found in the
Supplementary Text. The threshold for replication was set at
Bonferroni-corrected P < 1.9 × 10−3 (0.05/28 tests). There were 38
BMI- or WC-associated CpGs carried forward for replication in
adipose tissue, and 10 were removed in QC procedures in
MuTHER cohort and not tested.
Supplementary Material
Supplementary Material is available at HMG online.
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